Compare · ILMN vs PSNL
ILMN vs PSNL
Side-by-side comparison of Illumina Inc. (ILMN) and Personalis Inc. (PSNL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ILMN and PSNL operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $28.24B, about 17.5x PSNL ($1.61B).
- Over the past year, ILMN is up 94.2% and PSNL is up 149.4% - PSNL leads by 55.2 points.
- ILMN has been more active in the news (11 items in the past 4 weeks vs 10 for PSNL).
- ILMN has more recent analyst coverage (25 ratings vs 14 for PSNL).
- Company
- Illumina Inc.
- Personalis Inc.
- Price
- $186.76-1.85%
- $15.39-1.25%
- Market cap
- $28.24B
- $1.61B
- 1M return
- +13.80%
- +58.99%
- 1Y return
- +94.24%
- +149.43%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- 2019
- News (4w)
- 11
- 10
- Recent ratings
- 25
- 14
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Personalis Inc.
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves biopharmaceutical customers, universities and non-profits, diagnostics companies, and government entities. The company has partnership with Berry Genomics; Natera, Inc.; and MapKure, LLC. Personalis, Inc. was founded in 2011 and is headquartered in Menlo Park, California.
Latest ILMN
- Illumina expands Billion Cell Atlas program with new AI drug developers
- Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
- Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer
- Director Meister Keith A. was granted 142 shares, increasing direct ownership by 2% to 6,780 units (SEC Form 4)
- Director Ullem Scott B. was granted 167 shares, increasing direct ownership by 2% to 11,030 units (SEC Form 4)
- Bernstein resumed coverage on Illumina with a new price target
- Chief Legal Officer Davies Scott M sold $110,700 worth of shares (615 units at $180.00), decreasing direct ownership by 3% to 20,953 units (SEC Form 4)
- Director Skovronsky Daniel was granted 1,674 shares (SEC Form 4)
- SEC Form 3 filed by new insider Skovronsky Daniel
- Illumina Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
Latest PSNL
- President and CMO Chen Richard exercised 100,000 shares at a strike of $2.44 and sold $1,515,000 worth of shares (100,000 units at $15.15) as part of a pre-agreed trading plan (SEC Form 4)
- Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain
- Chief Executive Officer Hall Christopher M exercised 100,000 shares at a strike of $1.61 and sold $1,508,000 worth of shares (100,000 units at $15.08) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Personalis Inc.
- CFO AND COO Tachibana Aaron sold $69,748 worth of shares (4,982 units at $14.00) as part of a pre-agreed trading plan and exercised 4,982 shares at a strike of $5.32 (SEC Form 4)
- SEC Form 144 filed by Personalis Inc.
- CFO AND COO Tachibana Aaron exercised 51,251 shares at a strike of $7.48 and sold $675,488 worth of shares (51,251 units at $13.18) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Hall Christopher M exercised 100,000 shares at a strike of $1.61 and sold $1,315,000 worth of shares (100,000 units at $13.15) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Personalis Inc.
- SEC Form 144 filed by Personalis Inc.